In patients with low systemic blood pressure, care should be taken to avoid further hypotension.
Symptoms that may indicate the diagnosis include unexplained severe pain that increases rapidly over time associated with systemic toxicity including hypotension.
The effectiveness of most vasodilators is, however, reduced in the hypertensive lung and they cause systemic hypotension.
It is unclear whether the effect of tacrolimus is due to systemic immunosuppression or a local effect.
Cancer vaccines are currently being developed to confer active, specific immunotherapy directed against tumor-associated antigens, while inducing minimal systemic toxicity.